Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study.
Lawen
J
J
Kidney Transplant Program, Department of Urology, QE Health Science Center, Halifax, Nova Scotia, Canada.
Keough-Ryan
T
T
Clase
C
C
Kiberd
B
B
D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D000077552:Basiliximab; D002784:Cholesterol / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000187:drug effects / Q000254:growth & development; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010865:Pilot Projects; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011993:Recombinant Fusion Proteins; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D002784:Cholesterol; D000077552:Basiliximab; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus; D000212:Acyclovir